Matinas BioPharma Holdings (MTNB) Receivables - Other (2015 - 2023)
Matinas BioPharma Holdings (MTNB) posted quarterly Receivables - Other of $4.6 million for Q4 2023, up 5607.3% quarter-over-quarter from $79810.0 in Q3 2015.
Matinas BioPharma Holdings (MTNB) Receivables - Other (2015 - 2023) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has reported Receivables - Other for 2 consecutive years, with $4.6 million the latest figure, recorded in Q4 2023.
- In Q4 2023, Receivables - Other changed N/A year-over-year to $4.6 million; the TTM figure through Dec 2023 stood at $4.6 million (changed N/A YoY), while the FY2023 annual figure was $4.6 million, changed N/A from the prior year.
- Receivables - Other improved to $4.6 million in Q4 2023 per MTNB's latest filing, from $79810.0 in the prior quarter.
- Across five years, Receivables - Other topped out at $4.6 million in Q4 2023 and bottomed at $4.6 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.99 Bn | 132.14 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.80 Bn | 78.80 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.38 Bn | 60.19 Bn | 1.37 Bn |
| 4 | Moderna | 60.70 Bn | 55.56 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.22 Bn | 37.12 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.45 Bn | 10.06 Bn | 668.28 Mn |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.21 Bn | 26.37 Bn | - |
| 10 | Matinas BioPharma Holdings | 1.22 Mn | 406,176.27 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 4.56 Mn |
| Dec 31, 2023 | 4.56 Mn |
| Sep 30, 2015 | 79,810.00 |
| Sep 30, 2015 | 79,810.00 |